舒利迭与布地奈德吸入治疗支气管哮喘临床效果比较

目的:比较沙美特罗/丙酸氟替卡松干粉剂(舒利迭)与布地奈德干粉剂吸入治疗成年支气管哮喘患者的临床效果。方法:将78例成年哮喘患者随机分为试验组和对照组各39例,试验组采用舒利迭吸入治疗,对照组采用布地奈德吸入治疗。治疗6周,观察两组短效β2-受体激动剂(沙丁胺醇喷雾剂)的使用次数、日间及夜间症状评分的变化。结果:试验组及对照组治疗后与治疗前的沙丁胺醇喷雾剂使用次数、日间及夜间症状评分都有明显变化,试验组治疗效果优于对照组。结论:与单纯糖皮质激素相比,联合糖皮质激素和长效β2-受体激动剂对哮喘的疗效更佳。     

舒利迭治疗儿童中、重度哮喘50例疗效分析

[目的]观察舒利迭治疗儿童中、重度哮喘的疗效。[方法]对门诊及住院的50例5-14岁中、重度哮喘患儿子舒利迭干粉吸入剂治疗,观察哮喘评分变化,速效82激动剂使用次数及肺功能。[结果]本组50例中显效44例,占88％,有效6例,占12％,总有效率100％。本组患儿哮喘症状评分明显降低（P〈0.001）,速效β2激动剂使用次数较治疗前明显减少（P〈0.05）,肺功能最大峰流速值（PEF）较治疗前明显改善（P〈0.01）。[结论]舒利迭干粉吸入剂治疗儿童中、重度哮喘起率快、疗效佳。     

舒利迭治疗支气管哮喘60例疗效观察

目的:观察舒利迭治疗支气管哮喘的疗效。方法:60例确诊为支气管哮喘的患者予吸入舒利迭100-200μg/次,每日2次,共用8周。观察吸入前后临床症状变化、肺功能及药物反应。结果:支气管哮喘患者经舒利迭吸入治疗哮喘症状明显改善,治疗后患者第一秒用力呼气容积(FEV1)、用力呼气峰流速(PEF)显著提高。仅5例(占8.3%)患者出现轻微不良反应。结论:吸入舒利迭治疗支气管哮喘有较好的临床疗效,不良反应少。     

舒利迭与普米克吸入治疗儿童轻度哮喘的疗效比较

目的比较舒利迭与普米克吸入治疗儿童轻度哮喘的临床效果。方法选取2008年12月-2011年12月在我院接受治疗的轻度哮喘患儿46例,随机分为对照组和研究组各23例。研究组给予患儿舒利迭吸入治疗,对照组则采用普米克吸入治疗。结果治疗前,两组患儿的哮喘发作次数、吸入短效β2受体激动剂（硫酸沙丁胺醇：万托林）次数以及患者PEF值均无显著性差异（P〉0.05）,治疗4、8周时,研究组的PEF值增高幅度明显高于对照组,且哮喘发作次数、吸入短效β2受体激动剂次数均比对照组有明显减少（P〈0.05）。治疗2周时,两组的哮喘发作次数、吸入短效β2受体激动剂次数以及患者PEF值均无显著性差异（P〉0.05）。讨论舒利迭治疗儿童轻度哮喘,能明显帮助患儿消除症状,促进肺功能恢复,控制哮喘发作,治疗效果明显优于单纯皮质激素药物普米克,且使用便捷,安全可靠,值得临床推广。     

舒利迭吸入治疗儿童哮喘疗效观察

目的观察舒利迭吸入治疗儿童哮喘的临床疗效。方法对40例哮喘患儿按病情轻、中、重度分别予以不同剂量的舒利迭治疗,观察12周。治疗期间记录哮喘日记,沙丁胺醇气雾剂使用情况。治疗前后PEF值,不良反应。结果40例患儿临床症状评分减少,使用沙丁胺醇气雾剂次数明显减少,PEFR值占预计值的百分比增加,肺功能改善,总有效率95%。结论应用舒利迭治疗哮喘具有显著疗效,临床应用安全,副作用少,依从性好,适用于儿童哮喘的长期治疗。     

沙美特罗/丙酸氟替卡松治疗哮喘的临床疗效观察

目的比较沙美特罗/氟替卡松复方制剂舒利迭(SFC)与单用吸入糖皮质激素(ICS)布地奈德粉吸入剂治疗哮喘的疗效。方法50例成年轻中度哮喘患者分为两组:(1)SFC组(32例)使用SFC50/250μg,吸入,每日2次,治疗4周;(2)ICS组(18例),每次400ug布地奈德粉吸入剂,每日2次,治疗4周。观察哮喘日间症状评分、夜间憋醒次数及最大呼气流速(PEF)的变化。结果治疗后SFC组平均症状缓解时间为3天,而ICS组为9天(P<0.001)。治疗4周SFC组哮喘日间症状评分减少2分,ICS组减少1分(P<0.05),夜间憋醒次数两组分别减少1次,0次(P<0.05);治疗4周肺功能有效率SFC组和ICS组分别为71%、46%(P<0.05)。结论改善轻中度哮喘患者的症状及肺功能,SFC相比于单用ICS更快、更有效。     

舒利迭与普米克吸入治疗中重度哮喘疗效观察

目的：评价吸入舒利迭治疗中重度哮喘的疗效。方法：选取中重度哮喘患者43例，随机分为两组，治疗组26例，观察组17例。均在初诊及治疗第1、3、6个月详细记录哮喘每周发作次数、每天吸入短效β2激动剂的次数及呼气峰流数（PEFR）。结果：初治时两组患者的发病次数、吸入短效β2激动剂及PEFR无明显差异（P〉0．5）；治疗后1、3、6个月时舒利迭组发病次数、吸入短效β2激动剂次数明显少于普米克组，PEFR明显增加，有明显差异（P〈0．01）。结论：吸入舒利迭治疗中重度哮喘安全可靠。     

支气管哮喘联合治疗前后肺功能及临床评价

目的:通过肺功能监测对支气管哮喘患者进行分级治疗,观察联合应用沙美特罗/丙酸氟替卡松对中重度哮喘的治疗作用.方法:本试验为自身前后对照研究,经肺功能测定筛选出56例中重度支气管哮喘,吸入舒利迭50/250(每泡含沙美特罗50ug,氟替卡松250ug),1泡/次,每日2次,连续用3个月.结果:1.用力肺活量(FVC)、第一秒用力呼气容积(FEV1)、最大用力呼气流速FEFmax.用力呼出25%～75%肺活量时的瞬间流速FEF25%-75%与治疗前相比差异具有统计学意义(P≤0.001).2.日间症状评分较治疗前减少(78.3%),夜间症状评分较治疗前减少(80%),夜间憋醒次数较治疗前减少(90.3%),全天无症状天数明显增加,使用速效β2受体激动剂(喘乐宁)的次数较治疗前减少(76.9%).结论:1.肺功能测定对支气管哮喘分级具有重要意义.2.舒利迭能够控制大多数成人中重度哮喘患者的症状,改善肺功能和生活质量,具有良好的依从性和安全性.     

成人咳嗽变应性哮喘40例诊治分析

目的:总结成人咳嗽变应性哮喘的诊治经验。方法:采用舒利迭雾化吸入治疗咳嗽变异性哮喘成人患者40例,均于治疗2周观察临床疗效及治疗前后症状、体征、呼气峰值流速(PEF)的变化情况。结果:40例患者经治疗临床控制26例(占65.00%),显效8例(占20.00%),有效4例(占10.00%),无效2例(占5.00%),总有效率为95.00%。日间症状评分、夜间症状评分、PEF占预计值的百分比治疗后与治疗前相比,差异有统计学意义(P<0.05)。结论:舒利迭雾化吸入治疗成人咳嗽变异性哮喘临床疗效好。     

舒利迭治疗儿童哮喘40例疗效分析

目的 观察舒利迭治疗儿童哮喘的疗效.方法 对门诊及住院40例4～14岁,中、重度哮喘患儿予舒利迭干粉吸入剂治疗,每次50μg,每日2次,共用12周.观察哮喘评分变化,速效β2激动剂使用次数及肺功能(呼吸峰流速值的变化).结果 观察组患儿哮喘症状评分降低(P＜0.001),速效β2激动剂使用次数较治疗前明显减少(P＜0.05),肺功能呼吸峰流速(PEFR)值较治疗前明显改善(P＜0.01).显效36例,占90%,有效4例,占10%,总有效率100%.结论 舒利迭干粉吸入剂治疗儿童中、重度哮喘起率快、疗效佳,可明显减少皮质激素用量,患儿用药依从性好.可以使更多的患儿达到哮喘的完全控制.     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

Dr.Zhang Ren''''s Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.     

Luo Lingjie''''s Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

猪肺磷脂注射液联合经鼻持续气道正压通气对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性的影响

目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P＜0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P＜0.05),PaCO2均随观察时间的延长而降低(P＜0.05).观察组治疗有效率为87.5％,显著高于对照组的70.0％ (P ＜0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P＜0.05),且观察组明显低于对照组(P＜0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.     

Survey and practice of reporting quality of randomized controlled clinical trials on traditional Chinese medicine

Evidence obtained from randomized controlled trials （RCTs） has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine （TCM） and results have shown that there is an urgent need for higher quality RCTs on TCM.     

TCM Treatment of Ankylosing Spondylitis by Tonifying the Kidney and Strengthening the Governor Vessel

Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.     

IMPROVING P-gp EXPRESSION IN HUMAN MONONUCLEAR CELLS IN VITRO TRANSFECTED BY MULTIDRUG RESISTANCE-1 mRNA

CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…